Amneal Pharmaceuticals (AMRX) Gross Profit (2017 - 2026)

Amneal Pharmaceuticals has reported Gross Profit for 10 years, with the latest figure at $334.5 million in Q2 2026.

• On a quarterly basis, Gross Profit rose 16.86% year-over-year to $334.5 million in Q2 2026; TTM through Jun 2026 was $1.2 billion, a 14.07% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 9.1% from the prior year.
• Gross Profit was $334.5 million for Q2 2026 at Amneal Pharmaceuticals, up from $320.1 million in the prior quarter.
• The five-year high for Gross Profit was $334.5 million in Q2 2026, with the low at $174.6 million in Q1 2022.
• Average Gross Profit over 5 years is $244.1 million, with a median of $244.0 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Gross Profit fell 11.87% in 2023, then jumped 38.48% in 2024.
• Over 5 years, Gross Profit stood at $215.4 million in 2022, then decreased by 11.87% to $189.8 million in 2023, then jumped by 38.48% to $262.9 million in 2024, then rose by 13.05% to $297.2 million in 2025, then climbed by 12.56% to $334.5 million in 2026.
• The last three Gross Profit figures came in at $334.5 million (Q2 2026), $320.1 million (Q1 2026), and $297.2 million (Q4 2025), per Business Quant data.